Business Wire

Takeda Reports FY2016 Full Year Results and Issues FY2017 Guidance

10.5.2017 06:00 | Business Wire

Del

Takeda Pharmaceutical Company Limited (TOKYO:4502):

Delivered substantial profit growth versus prior year

  • Underlying Revenue grew +6.9%, with Takeda's Growth Drivers (GI, Oncology, CNS and Emerging Markets) delivering growth of +14.7%, and Underlying Revenue growth across all regions (U.S. +12.8%, Japan +5.0%, Europe & Canada +4.7%, Emerging Markets +4.5%). Reported revenue declined -4.2%, due to unfavorable currencies (-6.6pp) and the impact of divestitures (-4.5pp).
  • Underlying Core Earnings advanced +24.2%, with the Core Earnings margin increasing by 180bps. Despite unfavorable currencies and the negative impact of divestitures, reported operating profit was up +19.1%, benefiting from strong underlying growth and a one-time gain on the Teva JV transaction.
  • Underlying Core EPS was up +20.9%, reflecting strong Core Earnings growth. Reported EPS was 147 yen, an increase of +43.9% from 102 yen in the prior year.
  • Adjusted Operating Free Cash Flow was 158.8 billion yen, higher than our dividend payment for the second consecutive year.

Takeda's Growth Drivers delivered +14.7% Underlying Revenue growth

  • GI underlying revenue +33.5%, driven by ENTYVIO® and TAKECAB®.
  • Oncology underlying revenue +7.5%, supported by uptake of NINLARO® and ADCETRIS®.
  • CNS underlying revenue +26.7%, underpinned by strong performance of TRINTELLIX®.
  • Emerging Markets underlying revenue +4.5%, with the key markets of China, Russia and Brazil contributing to growth.

Christophe Weber, President and Chief Executive Officer of Takeda, commented:
"Our impressive performance in FY2016 highlights the success of Takeda's strategic transformation.
Our Growth Drivers maintained their strong momentum, and through revenue growth and disciplined expense management, we substantially increased our profit growth.
I am confident that Takeda will continue to deliver profit and margin growth over the mid-term, and a strong pipeline in the long-term, as we continue to execute our transformation."

Reported Results for FY2016 (April – March)

(billion yen)   FY2015   FY2016   Growth
Reported     Underlying 2
Revenue 1,807.4 1,732.1 -4.2%     +6.9%
Core Earnings1 292.0 245.1 -16.0% +24.2%
Operating Profit 130.8 155.9 +19.1% N/A
Net Profit3 80.2 114.9 +43.4% N/A
EPS 102 yen 147 yen +43.9% N/A
Core EPS   255 yen   220 yen   -13.6%     +20.9%

1

  Core Earnings is calculated by taking reported Gross Profit and deducting SG&A expenses and R&D expenses. In addition, certain other items that are non-core in nature and significant in value may also be adjusted.

2

Underlying growth compares two periods of financial results on a common basis, showing the ongoing performance of the business excluding the impact of foreign exchange and divestitures from both periods.

3

Attributable to the owners of the company.
 

FY2017 Management Guidance:

Takeda will boost

margins and drive continued profitable growth

    Guidance (growth %)
Underlying Revenue Low single digit
Underlying Core Earnings Mid-to-high teen
Underlying Core EPS Low-to-mid teen
Annual dividend per share   180 yen
 

FY2017 Reported Forecast:

Reported EPS

in FY2017 is forecast to increase 20% to 177 yen per share

(billion yen)   FY2016 Results   FY2017 Forecast   % change
Revenue 1,732.1 1,680.0 -3.0%
Operating Profit 155.9 180.0 +15.5%
Net Profit 114.9 138.0 +20.1%
EPS 147 yen   177 yen   +20.1%

Exchange Rate
(annual average)

 

1 US$= 109 yen
1 euro= 120 yen

 

1 US$= 110 yen
1 euro= 120 yen

 

For more details on Takeda’s FY2016 results and other financial information please visit https://www.takeda.com/investors/reports/

About Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited is a global research and development-driven pharmaceutical company committed to bringing better health and a brighter future to patients by translating science into life-changing medicines. Takeda focuses its R&D efforts on oncology, gastroenterology and central nervous system therapeutic areas plus vaccines. Takeda conducts R&D both internally and with partners to stay at the leading edge of innovation. New innovative products, especially in oncology and gastroenterology, as well as our presence in Emerging Markets, fuel the growth of Takeda. More than 30,000 Takeda employees are committed to improving quality of life for patients, working with our health care partners in more than 70 countries. For more information, visit http://www.takeda.com/news.

Contact information

Takeda Pharmaceutical Company Limited
Investor Relations
+81-(0)3-3278-2306
takeda.ir.contact@takeda.com
Media Relations
Tsuyoshi Tada, +81 (0)3-3278-2417
tsuyoshi.tada@takeda.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

The Valence Group Issues Fairness Opinion to SK Capital in Connection with Archroma18.8.2017 13:30Pressemelding

The Valence Group has provided a fairness opinion to SK Capital Partners, LP in connection with its recapitalization of Archroma, including investments made by various affiliates of SK Capital. Terms of the transaction were not disclosed. About SK Capital SK Capital is a private investment firm focused on the specialty materials, chemicals and pharmaceutical sectors. The firm builds strong and growing businesses that generate substantial long-term value for its investors. SK Capital utilizes its industry, operating and investment experience to identify opportunities to transform businesses into higher performing companies with improved strategic positioning, growth, profitability and risk profiles. The firm currently has approximately $1.9 billion of assets under management and its portfolio companies generate revenues of over $5.0 billion annually and employ approximat

Biker Summer 2017 campaign: What’s happening during Biker Summer 2017? Moto-tyres.co.uk is giving away exciting prizes!18.8.2017 09:22Pressemelding

Whether it’s a short weekend break or a long-distance tour – once again this year Moto-tyres.co.uk is asking bikers from 10 countries about their dream destinations and longest journeys as part of its “Biker Summer 2017” campaign. To ensure than nothing gets in the way of your next tour, the two-wheeler tyre store from Delticom, Europe’s leading online tyre dealer, is entering anyone who completes the survey before 30 September 2017 into a prize draw to win some great biking accessories. Simply answer three short questions about your plans for bike tours this year (don’t forget to provide your name and email address), and with a bit of luck, you might win one of these great prizes. Up for grabs are a GARMIN motorbike GPS system, a GoPro camera with helmet bracket and five 200-Pound vouchers for new motorbike tyres from the online store – thanks to the product range at Moto-tyres.co.uk, eve

Lenovo Continues to Gain Momentum in First Quarter FY 2017/1818.8.2017 00:04Pressemelding

Behind the strength of its 3-wave strategy, Lenovo’s business transformation continued to gain traction during the first quarter, delivering solid profitability in its core PC and smart devices business, and revenue and profit improvements in targeted growth areas, including the data center and mobile businesses. Fueled by new investments in people and products, Lenovo’s Data Center Group (DCG) introduced the most comprehensive product lineup in its history, with the new ThinkSystem and ThinkAgile portfolio, and continued to build out its end-to-end sales organization. Similarly, Lenovo’s Mobile Business Group launched significant new products led by the Moto Z2 Force, available now on all major U.S. carriers, and ramped up its branding efforts worldwide. “In the first quarter this fiscal year, we had stable performance as we executed our 3-wave strategy with commitment. We

Spirent Tests Wi-Fi Network Performance with O2 at the Coca-Cola London Eye17.8.2017 15:57Pressemelding

Spirent Communications plc (LSE:SPT), today announced its Landslide E10 network test platform has been used with O2 to validate the Wi-Fi network performance and capacity at the Coca-Cola London Eye, before the launch of a new smartphone application last month. This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170817005758/en/ Spirent Landslide E10 helped O2 validate Wi-Fi performance and capacity at the Coca-Cola London Eye, before the launch of a new smartphone application last month. (Photo: Busines Wire) Merlin Entertainments plc, operator of the London Eye, wanted to measure its Wi-Fi network performance, to ensure its infrastructure could provide an excellent experience for users of the new app, which puts increased demands on the Wi-Fi network. “The London Eye is a global attractio

Watch BizWireTV: A Camera You Can Wear and Krispy Kreme’s Famous Donuts Get Eclipsed with Chocolate17.8.2017 12:08Pressemelding

On BizWireTV, catch some Quick Biz Hits and see the latest in Star Power. Also see what’s happening in the startup world with the Accelerator Report, featuring the VC Watch and this week’s Startup Standout. This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170817005305/en/ BizWireTV is hosted by Jordyn Rolling (Photo: Business Wire Now you can watch BizWireTV, and the latest breakthroughs in tech from the biggest brands, on any screen you want by downloading the new app through the Apple TV and iPhone App Store and Google Play for Android devices. Top of the Wire Introducing FrontRow: the camera re-invented. Watch BizWireTV to see more disruptors as well as the top 5 trending stories of the week! A core c

PsiOxus Therapeutics Announce Two New Board Appointments: New Board Appointments Strengthen Company’s US Presence17.8.2017 07:00Pressemelding

PsiOxus Therapeutics, Ltd. (PsiOxus) today announced the appointment of Charles Rowland and Duncan Higgons to the Board of Directors as part of an ongoing drive to expand in the US. Charles Rowland was most recently the President and Chief Executive Officer (CEO) of Aurinia Pharmaceuticals, a clinical stage pharmaceutical company focused on the global lupus nephritis market. Prior to this, he served as the Vice President and Chief Financial Officer (CFO) of ViroPharma, during which time the company grew into a global biopharmaceutical business with $500 million in annual revenues until it was acquired by Shire plc for $4.2 billion. Before joining ViroPharma, Mr. Rowland was executive Vice President, CFO, and interim co-CEO, for Endo Pharmaceuticals. In his earlier career, Charles held finance and operational positions at Biovail Pharmaceuticals, Breakaway Technologies, Pharmacia

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom